PortfoliosLab logoPortfoliosLab logo
GNOM vs. QYLD
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

GNOM vs. QYLD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Global X Genomics & Biotechnology ETF (GNOM) and Global X NASDAQ 100 Covered Call ETF (QYLD). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GNOM achieves a 11.56% return, which is significantly higher than QYLD's 7.88% return.


GNOM

1D
3.47%
1M
11.33%
YTD
11.56%
6M
9.34%
1Y
57.90%
3Y*
0.45%
5Y*
-9.59%
10Y*

QYLD

1D
0.00%
1M
1.40%
YTD
7.88%
6M
9.91%
1Y
23.70%
3Y*
13.76%
5Y*
8.43%
10Y*
9.81%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GNOM vs. QYLD - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
GNOM
Global X Genomics & Biotechnology ETF
11.56%18.65%-15.99%-8.63%-36.27%-15.93%51.52%1.56%
QYLD
Global X NASDAQ 100 Covered Call ETF
7.88%9.28%19.35%22.77%-19.08%10.41%8.72%10.91%

Correlation

The correlation between GNOM and QYLD is 0.44, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.44

Correlation (3Y)
Calculated over the trailing 3-year period

0.45

Correlation (5Y)
Calculated over the trailing 5-year period

0.54

Correlation (All Time)
Calculated using the full available price history since Apr 11, 2019

0.55

The correlation between GNOM and QYLD shifts across timeframes, from 0.44 (1 year) to 0.55 (all time), reflecting how their relationship changes across market environments.

GNOM vs. QYLD - Sectors Allocation Comparison


Sectors
GNOM
QYLD

Healthcare

99.6%
4.2%

Technology

0.4%
53.8%

Basic Materials

-

1.1%

Communication Services

-

15.8%

Consumer Cyclical

-

12.3%

Consumer Defensive

-

7.7%

Energy

-

0.6%

Financial Services

-

0.2%

Industrials

-

2.8%

Real Estate

-

0.1%

Utilities

-

1.4%

Healthcare

GNOM
99.6%
QYLD
4.2%

Technology

GNOM
0.4%
QYLD
53.8%

Basic Materials

GNOM

-

QYLD
1.1%

Communication Services

GNOM

-

QYLD
15.8%

Consumer Cyclical

GNOM

-

QYLD
12.3%

Consumer Defensive

GNOM

-

QYLD
7.7%

Energy

GNOM

-

QYLD
0.6%

Financial Services

GNOM

-

QYLD
0.2%

Industrials

GNOM

-

QYLD
2.8%

Real Estate

GNOM

-

QYLD
0.1%

Utilities

GNOM

-

QYLD
1.4%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GNOM vs. QYLD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNOM
GNOM Risk / Return Rank: 6262
Overall Rank
GNOM Sharpe Ratio Rank: 6767
Sharpe Ratio Rank
GNOM Sortino Ratio Rank: 6868
Sortino Ratio Rank
GNOM Omega Ratio Rank: 5858
Omega Ratio Rank
GNOM Calmar Ratio Rank: 6666
Calmar Ratio Rank
GNOM Martin Ratio Rank: 5454
Martin Ratio Rank

QYLD
QYLD Risk / Return Rank: 8989
Overall Rank
QYLD Sharpe Ratio Rank: 8686
Sharpe Ratio Rank
QYLD Sortino Ratio Rank: 8787
Sortino Ratio Rank
QYLD Omega Ratio Rank: 9292
Omega Ratio Rank
QYLD Calmar Ratio Rank: 8686
Calmar Ratio Rank
QYLD Martin Ratio Rank: 9494
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNOM vs. QYLD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and Global X NASDAQ 100 Covered Call ETF (QYLD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GNOMQYLDDifference
Sharpe ratioReturn per unit of total volatility

-0.59

Sortino ratioReturn per unit of downside risk

-0.83

Omega ratioGain probability vs. loss probability

1.35

1.63

-0.28

Calmar ratioReturn relative to maximum drawdown

3.20

4.79

-1.59

Martin ratioReturn relative to average drawdown

9.21

28.10

-18.89

GNOM vs. QYLD - Sharpe Ratio Comparison

The current GNOM Sharpe Ratio is 2.18, which is comparable to the QYLD Sharpe Ratio of 2.78. The chart below compares the historical Sharpe Ratios of GNOM and QYLD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


GNOMQYLDDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.18

2.78

-0.59

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.29

0.58

-0.86

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.63

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.07

0.59

-0.66

Drawdowns

GNOM vs. QYLD - Drawdown Comparison

The maximum GNOM drawdown since its inception was -75.00%, which is greater than QYLD's maximum drawdown of -24.75%. Use the drawdown chart below to compare losses from any high point for GNOM and QYLD.


Loading charts...

Drawdown Indicators


GNOMQYLDDifference

Max Drawdown

Largest peak-to-trough decline

-75.00%

-24.75%

-50.25%

Max Drawdown (1Y)

Largest decline over 1 year

-18.17%

-4.97%

-13.20%

Max Drawdown (3Y)

Largest decline over 3 years

-46.47%

-19.06%

-27.41%

Max Drawdown (5Y)

Largest decline over 5 years

-72.29%

-24.61%

-47.68%

Max Drawdown (10Y)

Largest decline over 10 years

-24.75%

Current Drawdown

Current decline from peak

-53.90%

-0.06%

-53.84%

Average Drawdown

Average peak-to-trough decline

-40.56%

-3.84%

-36.72%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.30%

0.85%

+5.45%

Volatility

GNOM vs. QYLD - Volatility Comparison

Global X Genomics & Biotechnology ETF (GNOM) has a higher volatility of 8.77% compared to Global X NASDAQ 100 Covered Call ETF (QYLD) at 1.84%. This indicates that GNOM's price experiences larger fluctuations and is considered to be riskier than QYLD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GNOMQYLDDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.77%

1.84%

+6.93%

Volatility (6M)

Calculated over the trailing 6-month period

19.72%

7.12%

+12.60%

Volatility (1Y)

Calculated over the trailing 1-year period

26.66%

8.57%

+18.09%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

33.61%

14.70%

+18.91%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

34.19%

15.49%

+18.70%

GNOM vs. QYLD - Expense Ratio Comparison

GNOM has a 0.50% expense ratio, which is lower than QYLD's 0.60% expense ratio.


Dividends

GNOM vs. QYLD - Dividend Comparison

GNOM's dividend yield for the trailing twelve months is around 1.23%, less than QYLD's 11.46% yield.


PositionTTM20252024202320222021202020192018201720162015
GNOM
Global X Genomics & Biotechnology ETF
1.23%1.37%0.00%0.00%0.00%0.03%0.14%0.00%0.00%0.00%0.00%0.00%
QYLD
Global X NASDAQ 100 Covered Call ETF
11.46%11.55%12.50%11.78%13.75%12.85%11.16%9.84%12.44%7.69%9.15%9.42%

Frequently Asked Questions


GNOM and QYLD have a correlation of 0.44, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

GNOM has higher volatility (8.77%) compared to QYLD (1.84%). In terms of maximum drawdown, GNOM dropped -75.00% vs QYLD's -24.75%.

On 5-year performance, QYLD leads with 8.43% vs -9.59% for GNOM. On fees, GNOM is cheaper at 0.50% per year. On volatility, QYLD has been the lower-risk option at 1.84%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 5-year period, QYLD has performed better with a 8.43% return vs -9.59%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

GNOM is cheaper with a 0.50% expense ratio, compared with 0.60% for QYLD.

QYLD has the higher dividend yield at 11.46%, compared with 1.23% for GNOM.

GNOM is categorized as Health & Biotech Equities, while QYLD is Nasdaq-100. GNOM tracks Solactive Genomics Index, while QYLD tracks CBOE NASDAQ-100 Buy Write V2. Their fees differ too: 0.50% for GNOM and 0.60% for QYLD.

QYLD currently has the higher Sharpe Ratio (2.78 vs 2.18), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GNOM and QYLD

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer